| dc.contributor |
Médecins Sans Frontières, Campaign for Access to Essential Medecins, Geneva, Switzerland; Médecins Sans Frontières, Khayelitsha, South Africa; Geneva Teaching Hospital, Geneva, Switzerland |
|
| dc.creator |
van Roey, J |
|
| dc.creator |
von Schoen-Angerer, T |
|
| dc.creator |
Ford, N |
|
| dc.creator |
Calmy, A |
|
| dc.date |
2008-07 |
|
| dc.date.accessioned |
2017-01-31T07:11:47Z |
|
| dc.date.available |
2017-01-31T07:11:47Z |
|
| dc.identifier |
Drug Discov Today 2008;13(13-14):601-5 |
|
| dc.identifier |
1359-6446 |
|
| dc.identifier |
18598916 |
|
| dc.identifier |
10.1016/j.drudis.2008.04.009 |
|
| dc.identifier |
http://hdl.handle.net/10144/37354 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/37354 |
|
| dc.identifier |
Drug Discovery Today |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/37354 |
|
| dc.description |
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority. |
|
| dc.language |
en |
|
| dc.relation |
http://www.sciencedirect.com/science/journal/13596446 |
|
| dc.rights |
Archived on this site by kind permission and copyright 2008 by Elsevier |
|
| dc.title |
How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals |
|
| dc.type |
Article |
|